Unaudited Financials for Quarter and Period ended 31st December 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.5 pts more than Nifty Microcap 250 and 5.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sandu Pharmaceuticals reported Q3 FY26 revenue from operations of Rs 1,876.09 lakhs, up 2.1% YoY from Rs 1,837.20 lakhs. Net profit jumped 75.5% YoY to Rs 97.51 lakhs from Rs 55.55 lakhs. For the nine months ended December 2025, revenue was nearly flat at Rs 5,308.10 lakhs versus Rs 5,312.32 lakhs last year, but profit after tax grew 40.9% to Rs 172.27 lakhs from Rs 122.25 lakhs. Profit before tax stood at Rs 190.83 lakhs (9M FY25: Rs 181.33 lakhs). No exceptional items were booked. Statutory auditor M/s Dileep & Prithvi issued a clean (unqualified) limited review report. The company operates in a single segment - Ayurvedic Proprietary Medicines.
Strong double-digit profit growth despite flat top-line indicates improving margins and tighter cost control, which is a positive signal for shareholders. Clean auditor opinion and absence of exceptional items add to investor confidence, though the small scale and revenue stagnation are worth watching.